Eli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 ShsEli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 ShsEli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 Shs

Eli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 Shs

No trades
See on Supercharts

Key facts today


Eli Lilly's Phase 3 ATTAIN-2 trial for orforglipron showed participants lost an average of 22.9 lbs and reduced A1C levels by up to 1.8%, prompting global regulatory submissions.
Eli Lilly received FDA breakthrough designation for olomorasib, combined with Merck's Keytruda, targeting advanced non-small cell lung cancer with a KRAS G12C mutation after positive trial results.
Analysts from HSBC, Morgan Stanley, and Truist are optimistic about Eli Lilly, with projections for Orforglipron sales reaching up to $25 billion annually by 2032.
Analyze the impactAnalyze the impact
Market capitalization
‪695.83 B‬USD
0.25USD
‪9.41 B‬USD
‪40.01 B‬USD
Beta (1Y)
0.06

About Eli Lilly and Company


CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
ARDEUT111192
FIGI
BBG000HFVYP1
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Check out other big names from the same industry as LLYD.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
LLY4217068
Eli Lilly and Company 3.7% 01-MAR-2045
Yield to maturity
Maturity date
Mar 1, 2045
LLY5871810
Eli Lilly and Company 4.2% 14-AUG-2029
Yield to maturity
Maturity date
Aug 14, 2029
LLY5750404
Eli Lilly and Company 4.5% 09-FEB-2029
Yield to maturity
Maturity date
Feb 9, 2029
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065
Yield to maturity
Maturity date
Oct 15, 2065
LLY6153504
Eli Lilly and Company 4.55% 15-OCT-2032
Yield to maturity
Maturity date
Oct 15, 2032
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
Yield to maturity
Maturity date
Feb 9, 2064
LLY.GW
Eli Lilly and Company 5.55% 15-MAR-2037
Yield to maturity
Maturity date
Mar 15, 2037
LLY6003396
Eli Lilly and Company 5.5% 12-FEB-2055
Yield to maturity
Maturity date
Feb 12, 2055
LLY5871809
Eli Lilly and Company 4.15% 14-AUG-2027
Yield to maturity
Maturity date
Aug 14, 2027
LLY6003481
Eli Lilly and Company 4.75% 12-FEB-2030
Yield to maturity
Maturity date
Feb 12, 2030
LLY.GG
Eli Lilly and Company 6.77% 01-JAN-2036
Yield to maturity
Maturity date
Jan 1, 2036

See all LLYD bonds